Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
03/08/26	US$7.160	+0.56%	21,465
31/07/26	US$7.120	-18.16%	109,321
30/07/26	US$8.700	-4.29%	729,320
29/07/26	US$9.090	+70.54%	7,916,034
28/07/26	US$5.330	+6.39%	17,363

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 03/08/2026 BST			5-day change	1st Jan Change
7.160 ^USD	+0.56%		+42.91%	-41.50%

04-29	SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-28	SciSparc Ltd. Auditor Raises 'Going Concern' Doubt	CI

Market Cap	4.1M 3.57M 3.33M 3.06M 5.76M 391M 5.87M 39.27M 15.38M 195M 15.42M 15.08M 643M	P/E 2024	-0.33x	P/E 2025	-0.12x
Enterprise Value	-121K -105K -97.84K -89.82K -169K -11.49M -172K -1.15M -452K -5.73M -453K -443K -18.9M	EV / Sales 2024	-551,308x	EV / Sales 2025	289,759x
Free-Float	100%	Yield 2024 *	-	Yield 2025	-

04-29	SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-28	SciSparc Ltd. Auditor Raises 'Going Concern' Doubt	CI
03-16	Neurothera Labs Inc. Clearmind Medicine Inc. Collaboration Leads to Patent Application for Depression Therapy	CI
03-16	Scisparc Neurothera Labs- Clearmind Medicine collaboration leads to patent application for depression therapy	RE
03-10	Clearmind Medicine Inc Announces Publication of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Metabolic Dysfunction-Associated Steatotic Liver Disease	CI
03-10	Top Premarket Decliners	MT
02-11	SciSparc Ltd. announced that it expects to receive $9 million in funding	CI
01-25	Neurothera Labs Inc. completed the acquisition of Portfolio of patents, trademarks, know-how of Xylo Technologies Ltd.	CI
01-13	SciSparc Subsidiary to Acquire Endoscopic Patents of Xylo Technologies in All-Stock Deal	MT
12-30	SciSparc Ltd.'s Equity Buyback announced on July 7, 2022, has expired.	CI
12-01	Scisparc plans on entering the multi-billion-dollar GERD device market with acquisition of an approved IP portfolio	RE
11-26	Scisparc to acquire treasury of patents for innovative medical endoscopy systems	RE
11-26	Scisparc shares climb 27.5% premarket; co says will buy a treasury of patents, trademarks and intellectual property rights from Xylo	RE

07-31	SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics	GL
07-30	SciSparc, Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company	AQ
07-29	SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company	GL
07-27	SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity	GL
07-15	SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome	GL

SciSparc Ltd. Share Price

Stocks

SPRC

IL0010951403

Pharmaceuticals

Valuation: SciSparc Ltd.

Chart: SciSparc Ltd.

Latest news : SciSparc Ltd.

Press Releases: SciSparc Ltd.

News in other languages: SciSparc Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: SciSparc Ltd.

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 day	+0.56%
1 week	+42.91%
Current month	+0.56%
1 month	+49.79%
3 months	-9.48%
6 months	+5.44%
Current year	-41.50%

1 week	5.57	11.51
1 month	4.23	11.51
Current year	2.98	15.79
1 year	2.98	80.1
3 years	2.98	2,997.05
5 years	0.49	41,769.08
10 years	0.49	41,769.08

Manager	Title	Age	Since
Oz Adler CEO	Chief Executive Officer	39	09/01/2022
Amitay Weiss CEO	Chief Executive Officer	62	20/08/2020
Adi Zuloff-Shani CTO	Chief Tech/Sci/R&D Officer	56	07/02/2016

Director	Title	Age	Since
Amitay Weiss CHM	Chairman	62	09/01/2022
Itschak Shrem CHM	Chairman	79	20/09/2025
Lior Vider BRD	Director/Board Member	50	20/08/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCISPARC LTD.	+0.56%	+42.91%	-85.97%	-99.66%	4.08M
SUN PHARMACEUTICAL INDUSTRIES LTD.	-1.36%	-0.52%	+20.48%	+72.09%	50.03B
OTSUKA HOLDINGS CO., LTD.	+2.74%	+3.60%	+60.17%	+127.09%	36.6B
CIPLA LIMITED	+0.08%	+4.61%	-1.89%	+26.47%	12.47B
ZYDUS LIFESCIENCES LIMITED	-0.51%	+1.16%	+18.12%	+75.16%	11.77B
KRKA, D. D.	-1.33%	-0.57%	+30.73%	+130.67%	9.04B
ONO PHARMACEUTICAL CO., LTD.	-1.16%	-4.49%	+39.70%	-13.85%	7.03B
GEDEON RICHTER	+1.10%	+1.62%	+14.71%	+33.59%	6.79B
GLENMARK PHARMACEUTICALS LIMITED	-0.17%	+1.55%	+7.84%	+181.51%	6.6B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-0.24%	-0.36%	-35.41%	+6.58%	5.49B
Average	-0.05%	+5.27%	+6.85%	+53.96%	14.58B
Weighted average by Cap.	+0.04%	+1.32%	+26.95%	+82.42%

	2024	2025
Net sales	1.31 1.14 1.06 0.97 1.83 124.48 1.87 12.5 4.89 62.08 4.91 4.8 204.75	0.86 0.74 0.69 0.64 1.2 81.59 1.22 8.19 3.21 40.69 3.22 3.14 134.2
Net income	-6.28M -5.46M -5.1M -4.68M -8.83M -599M -8.98M -60.12M -23.55M -299M -23.6M -23.08M -985M	-12.18M -10.58M -9.88M -9.07M -17.11M -1.16B -17.4M -117M -45.64M -579M -45.75M -44.73M -1.91B
Net Debt	-2.01M -1.75M -1.63M -1.5M -2.82M -192M -2.87M -19.24M -7.54M -95.59M -7.55M -7.39M -315M	-4.22M -3.67M -3.43M -3.15M -5.93M -403M -6.04M -40.42M -15.83M -201M -15.87M -15.52M -662M